Your Medical Director can help you decide if a single peptide or the Wolverine blend is right for your goals
Real-world outcomes from PlexusDx patients show consistent weight reduction alongside improvements in fasting blood glucose, cholesterol profiles, and self-reported energy levels
Impairment of the ubiquitinproteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures
Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
Many telehealth platforms serving Michigan, including HealthRX, bundle the consultation fee with medication delivery